Big pharma and health gare: Unsolvable conflict of interests between private enterprise and public health

Israel Journal of Psychiatry and Related Sciences

Volumn 45, Issue 2, 2008, Pages 83-89

  Brezis, Mayer ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49949085923     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Hardin G. The tragedy of the commons. Science 1968; 162: 1243-1248.
2. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-1709.
3. Snyder L, Leffler C. Ethics manual (5th edition). Ann Intern Med 2005:142:560-582.
4. Editorial. Prescription drug expenditures rising - too fast? CMAJ 2005;172:1261,1263.
5. Smith A. An inquiry into the nature and causes of the wealth of nations. Dublin: Whitestone, 1776.
6. Transparency International. Corruption and Health. 2006 http://www.transparency.org/publications/gcr/download_gcr.
7. Abramson J, Starfield B. The effect of conflict of interest on biomedical research and clinical practice guidelines: Can we trust the evidence in evidence-based medicine? J Am Board Fam Pract 2005;18:414-418.
8. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med 2006;354:1193.
9. Juni P, Reichenbach S, Egger M. COX 2 inhibitors, traditional NSAIDs, and the heart. BMJ 2005;330:1342-1343.
10. Waxman HA. The lessons of Vioxx - drug safety and sales. N Engl J Med 2005;352:2576-2578.
11. Saul S. Senators ask drug giant to explain grants to doctors. New York Times, July 6,2005; C p. 3.
12. Lenzer J. Drug secrets. What the FDA isn't telling. Slate. Sept. 27, 2005 http://www.slate.com/id/2126918/.
13. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ 2003;326:1171-1173.
14. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-638.
15. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events? JAMA 2003;290:921-928.
16. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. Public Library of Science Medicine 2005;2:e138.
17. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH. Randomized trials stopped early for benefit: A systematic review. JAMA 2005;294:2203-2209.
18. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, Neumann PJ. Bias in published cost effectiveness studies: Systematic review. BMJ 2006;332:699-703.
19. Abramson J. Overdosed America: The broken promise of American medicine. New York: Harper Collins, 2004.
20. Avorn J. Powerful medicines: The benefits, risks, and costs of prescription drugs. New York: Knopf, 2004.
21. Deyo RA, Patrick DL. Hope or hype: The obsession with medical advances and the high cost of false promises. New York: AMACOM, American Management Association, 2005.
22. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
23. Angell M. The truth about the drug companies: How they deceive us and what to do about it. New York: Random House, 2004.
24. Kassirer JP. On the take: How America's complicity with big business can endanger your health. New York: Oxford University, 2005.
25. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-617.
26. Law J. Big Pharma. Exposing the global healthcare agenda. New York: Carroll & Graf, 2006. Public Health/Politics.
27. Friedman LS, Richter ED. Excessive and disproportionate advertising in peer-reviewed journals. Int J Occup Environ Health 2006;12:59-64.
28. Lexchin J, Light DW. Commercial influence and the content of medical journals. BMJ 2006;332:1444-1447.
29. Moynihan R, Cassels A. Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients. New York, NY: Nation Books, 2005.
30. Phillips CB. Medicine goes to school: Teachers as sickness brokers for ADHD. Public Library of Science Medicine 2006;3:e182.
31. Tiefer L. Female sexual dysfunction: A case study of disease mongering and activist resistance. Public Library of Science Medicine 2006;3:e178.
32. Lexchin J. Bigger and better: How Pfizer redefined erectile dysfunction. Public Library of Science Medicine 2006;3:e132.
33. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273-1276.
34. Schafer A. Biomedical conflicts of interest: A defence of the sequestration thesis - learning from the cases of Nancy Olivieri and David Healy. J Med Ethics 2004;30:8-24.
35. Healy D. Good science or good business? Hastings Cent Rep 2000;30:19-22.
36. Healy D. Did regulators fail over selective serotonin reuptake inhibitors? BMJ 2006;333:92-95.
37. Healy D, Whitaker C. Antidepressants and suicide: Risk-benefit conundrums. J Psychiatry Neurosci 2003;28:331-337.
38. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-47.
39. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005;331:155-157.
40. Moncrieff J. Psychiatric drug promotion and the politics of neoliberalism. Br J Psychiatry 2006;188:301-302.
41. Steinbrook R. Standards of ethics at the National Institutes of Health. N Engl J Med 2005;352:1290-1292.
42. Okie S. Raising the safety bar - the PDA's coxib meeting. N Engl J Med 2005;352:1283-1285.
43. Avorn J. Torcetrapib and atorvastatin - should marketing drive the research agenda? N Engl J Med 2005;352:2573-2576.
44. Lenzer J. Bush plans to screen whole US population for mental illness. BMJ 2004;328:1458.
45. Lenzer J. Whistleblower removed from job for talking to the press. BMJ 2004;328:1153.
46. Cohen JE, Ashley MJ, Ferrence R, Brewster JM, Goldstein AO. Institutional addiction to tobacco. Tob Control 1999;8:70-74.
47. Michaels D. Doubt is their product. Sci Am 2005;292:96-101.
48. Nestle M. Food politics: How the food industry influences nutrition and health. Berkeley: University of California, 2002. California Studies in Food and Culture: 3 . 49. Markowitz GE, Rosner D. Deceit and denial: The deadly politics of industrial pollution. Berkeley: University of California, 2002.
49. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med 2006;99:337-341.
50. Evans I, Thornton H, Chalmers I. Testing treatments. Better research for better healthcare. London: British Library, 2006.
51. Siegel M, Doner L. Marketing public health: Strategies to promote social change. Gaithersburg, Maryland: Aspen, 1998.